The next wave of drug delivery might not come from a syringe or a pill bottle, but from a small coin-sized patch that dissolves into your skin. ArrayPatch, a biotech spinout from University College Cork (UCC), is developing a class of polymer-free dissolving microneedle patches designed to carry everything from antifungal drugs to GLP-1 peptides directly through the skin's outer layer [array-patch.com]. The company's technical bet is that by constructing the microneedles entirely from the active drug compound, it can achieve higher drug loading and a cleaner delivery profile than polymer-based alternatives [FinSMEs, November 2026].
A Technical Wedge in Transdermal Delivery
ArrayPatch's core technology, called DerMap, is a dissolvable microneedle patch where the microscopic needles themselves are made from the medicine. This polymer-free approach is the company's primary technical differentiator. In a conventional dissolving microneedle, the drug is embedded within a supporting polymer matrix that dissolves to release it. ArrayPatch's method eliminates that polymer, aiming to pack more active pharmaceutical ingredient into each needle and potentially simplify the regulatory pathway by reducing the number of materials introduced to the body [FinSMEs, November 2026]. The patch is designed to be pain-free and to fully dissolve after penetrating the stratum corneum, the skin's protective outer layer [array-patch.com].
The Three-Pronged Pipeline
The company is not putting all its capital behind a single indication. Instead, it has outlined a pipeline targeting three distinct therapeutic areas with significant market pull. This multi-program strategy spreads technical risk while aiming at large, validated markets.
| Metric | Value |
|---|---|
| Onychomycosis (ITZ-DerMap) | 6 B USD Market |
| Obesity/Diabetes (GLP-DerMap) | 0 Clinical Program |
| Basal-Cell Carcinoma (VIS-DerMap) | 0 Clinical Program |
- ITZ-DerMap for onychomycosis. This program, targeting nail fungal infections, is the lead asset and the stated focus for initial clinical proof-of-concept work. The company cites a total addressable market exceeding $6 billion, framing it as an area of significant unmet need where topical patches could offer a superior alternative to oral medications or invasive treatments [UCC, March 2025].
- GLP-DerMap for obesity and diabetes. This is perhaps the most ambitious program, aiming to deliver GLP-1 receptor agonists like semaglutide through a transdermal patch. Success here would tap into one of the most valuable pharmaceutical markets in decades, offering a potential alternative to weekly injections [UCC].
- VIS-DerMap for basal-cell carcinoma. The third program targets a common form of skin cancer, exploring localized, needle-free delivery of therapeutic agents directly to the tumor site [UCC].
The Academic Spinout Engine
ArrayPatch is a classic example of deep-tech company formation, spinning out of UCC in June 2024 [UCC, March 2025]. The founding team combines academic research with commercial intent. Dr. Waleed Faisal, the founder and CEO, led the commercialization effort, while Professor Abina Crean, a Professor of Pharmaceutics at UCC, is the co-inventor of the underlying DerMap technology [UCC, March 2025]. The company has since built out a management team with stated experience in microneedle manufacturing, regulatory strategy, and business development [UCC, March 2025]. Public profiles list Tord Labuda as Chief Scientific Officer, Ryan Bamsey as Chief Operating Officer, and Darren Cunningham as Chief Financial Officer [Dealroom.co].
| Role | Name | Background Anchor |
|---|---|---|
| CEO / Founder | Dr. Waleed Faisal | Led UCC spinout in June 2024 [UCC, March 2025] |
| Co-inventor | Prof. Abina Crean | Professor of Pharmaceutics, UCC [University College Cork] |
| CSO | Tord Labuda | Not specified in captured sources [Dealroom.co] |
| COO | Ryan Bamsey | Not specified in captured sources [Dealroom.co] |
| CFO | Darren Cunningham | Fractional CFO [Kritika Verma - Agile Executives |
Funding the Path to Human Trials
ArrayPatch has secured non-dilutive and venture capital to fund its progression from lab to clinic. The technology received more than €1 million in grant funding from Enterprise Ireland prior to March 2025 [UCC, March 2025]. This was followed by an oversubscribed seed financing round that totaled €3.2 million by November 2026 [Silicon Republic, November 2026]. The round was structured in two closes: a €3 million first close announced in February 2026, and an additional €1.6 million second close that brought the total to €3.2 million [Finance Yahoo, February 2026][FinSMEs, November 2026]. Investors include Lakeside Capital, Enterprise Ireland, The Boole Investment Syndicate, and DeepIE Ventures. The capital is earmarked for advancing the DerMap programs, with a focus on moving the GLP-1 and skin cancer candidates toward first-in-human studies [Silicon Republic, November 2026].
The Scale-Up Hurdles
The technical premise is elegant, but the path from a laboratory prototype to a manufactured, clinically validated, and regulated product is long and expensive. The polymer-free approach must prove it can achieve consistent, high-volume manufacturing of microneedle arrays where the drug substance itself forms the structural component. This is a materials science and process engineering challenge distinct from formulating a drug for a pill or a solution for injection.
Furthermore, each therapeutic program faces its own clinical valley of death. The GLP-1 patch, for instance, must demonstrate bioequivalence to injectable forms, a high bar for a new delivery mechanism competing against established, highly effective products. The capital raised, while significant for a seed round, is a down payment on the clinical trials required for any of these programs to reach the market. The company's own projections from early 2025 anticipated a need for an €8-10 million Series A to support trials and a target first product launch in the 2028/29 timeframe [UCC, March 2025]. Hitting those milestones will require demonstrating compelling early human data to attract that next level of funding.
ArrayPatch's bet rests on a clear technical breakdown: replace the polymer carrier with pure drug, increase payload, and simplify the delivery system. The sober assessment is that the company now has to prove that elegant concept can be manufactured at scale, consistently deliver therapeutic doses in humans, and navigate regulatory approval for three different disease states,all before its current capital runs out. The €3.2 million seed round buys the runway to generate the first critical human data points. Whether those data points validate the polymer-free thesis will determine if ArrayPatch's patches are a novel delivery method or a promising lab experiment.
Sources
- [array-patch.com] Array Patch | Microneedle Patch Technology | https://array-patch.com/
- [UCC, March 2025] ArrayPatch | https://www.ucc.ie/en/innovation/whatwedo/successstories/arraypatch/
- [Finance Yahoo, February 2026] ArrayPatch Announces First Close of €3M Seed Round | https://finance.yahoo.com/news/arraypatch-announces-first-close-3m-080100882.html
- [Silicon Republic, November 2026] ArrayPatch to take dissolving GLP-1 patches to human trials | https://www.siliconrepublic.com/start-ups/arraypatch-cork-biotech-funding-e3-2m-university-college-cork-drug-pharmaceutical
- [FinSMEs, November 2026] ArrayPatch Raises €1.6M in Second Close Of Seed Funding | https://www.finsmes.com/2026/11/arraypatch-raises-e1-6m-in-second-close-of-seed-funding.html
- [University College Cork] Abina Crean profile | https://www.ucc.ie/en/pharmacy/people/academicstaff/abinacrean/
- [Dealroom.co] ArrayPatch team data | https://www.dealroom.co/
- [Kritika Verma - Agile Executives | LinkedIn] Darren Cunningham reference | https://www.linkedin.com/in/kritika-verma-agile-executives/